Bookmark

Add to MyYahoo RSS

Osteoporosis News

News on Osteoporosis continually updated from thousands of sources around the net.

1 hr ago | Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

FirstMerit Corporation has publically announced that CFT I will b... )--Eighth paragraph, attribution should read: Patrick Soon-Shiong, M.D., CEO of NantBioScience . The corrected rel... )--Research and Markets has announced the addition of the "Global Household Appliances Industry 2014-2019:... Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis )--Merck announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis.

Comment?

Related Topix: Medicine, Health

5 hrs ago | Forbes.com

Merck's Osteoporosis Drug Meets Primary Fracture Endpoints In Phase 3 Trial

I'm a pharmacologist, freelance science and medical writer, educator, and speaker with a passion for public science communications. I earned a Ph.D. in pharmacology and therapeutics from the University of Florida and a B.S. in toxicology from the Philadelphia College of Pharmacy and Science.

Comment?

Related Topix: Medicine, Health, Pharmacology, University of Florida, Research Triangle Park, NC, Fosamax, Alendronate (generic), Healthcare Industry

6 hrs ago | Reuters

Long-delayed Merck osteoporosis drug meets goal in study

Merck & Co on Monday said it expects next year to seek U.S. approval for its long-delayed experimental osteoporosis drug, odanacatib, after the once-weekly medicine met its primary goals in a late-stage trial. The drug significantly reduced risk of fractures of the hip and spine, and of non-vertebral fractures, compared with placebo, Merck said in a release.

Comment?

Related Topix: Biotech, Merck , Medicine, Healthcare Industry, Health

6 hrs ago | Reuters

UPDATE 1-Long-delayed Merck osteoporosis drug meets goal in study

Merck & Co on Monday said it expects next year to seek U.S. approval for its long-delayed experimental osteoporosis drug, odanacatib, after the once-weekly medicine met its primary goals in a late-stage trial. The drug significantly reduced risk of fractures of the hip and spine, and of non-vertebral fractures, compared with placebo, Merck said in a release.

Comment?

Related Topix: Biotech, Merck , Medicine, Healthcare Industry, Health, Marketing

6 hrs ago | Seeking Alpha

Merck osteoporosis drug candidate successful in Phase 3 trial

Merck's odanacatib achieves its primary endpoints in a pivotal Phase 3 fracture outcomes study in post menopausal women with osteoporosis. Odanacatib reduced the relative risk of new and worsening morphometric vertebral fractures by 54%, clinical hip fractures by 47%, non-vertebral fractures by 23% and clinical vertebral fractures by 72%.

Comment?

Related Topix: Biotech, Merck , Medicine, Health, Healthcare Industry

10 hrs ago | CiteULike

Compliance with drug therapies for the treatment and prevention of osteoporosis.

This study used paid claims data from real-world treatment settings to investigate the impact of hormone replacement therapy , bisphosphonate and raloxifene on patients with a recorded diagnosis of osteoporosis. Data from a large health insurer were used to identify 58,109 osteoporosis patients who initiated drug therapy for osteoporosis.

Comment?

Related Topix: Medicine, Health, Evista, Raloxifene (generic)

14 hrs ago | CiteULike

The impact of compliance with osteoporosis therapy on fracture rates in actual practice.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA , Vol. 15, No.

Comment?

Related Topix: Medicine, Health

14 hrs ago | CiteULike

Interventions to improve osteoporosis medication adherence and...

Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA , Vol.

Comment?

Related Topix: Medicine, Health, Nursing

14 hrs ago | CiteULike

Compliance with pharmacologic therapy for osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA , Vol. 14, No.

Comment?

Related Topix: Medicine

Sat Sep 13, 2014

Ormskirk Advertiser

New firm breaking down the barriers in Ormskirk

Mednostic Solutions is a family-run business which says it offers the UK's first osteoporosis treatment of its kind, reported by Adam Payne Four members of an Ormskirk family are embarking on a business venture that they claim will offer a better approach to detecting and treating osteoporosis. Dexa Health, based at Total Fitness in Aintree, is made up of sisters Rachel Paglia and Joanne Kinsey, along with their husbands Ben Paglia and Dr Jack Kinsey.

Comment?

Related Topix: Lancashire County, England, World News, United Kingdom, Medicine, Health, Nursing, Marketing

Fri Sep 12, 2014

PR-inside.com

Global osteoporosis market: Latest market analysis presented

This report provides elemental information and data relating to the clinical trials on Osteoporosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.

Comment?

Related Topix: Medicine, Health

Thu Sep 11, 2014

News Max

Parathyroid Hormone Drug Effective in Trials

NPS Pharmaceuticals Inc soared on Wednesday after a preliminary report from U.S. regulators said its hormone replacement therapy Natpara, which could be approved by late next month, appears to be effective. The report, posted on Wednesday on the FDA's website, came two days ahead of a meeting of outside advisers to the agency who will discuss the drug and recommend whether it should be approved.

Comment?

Related Topix: Biotech, Medicine, NPS Pharmaceuticals, Healthcare Industry, Healthcare Law, Law

Sys-Con Media

Amgen Announces 23 Abstracts To Be Presented At The American Society...

The data that will be presented reinforce Amgen's continued commitment to discovering and developing novel treatments for patients suffering from bone-related diseases. Prolia data consist of 18 abstracts, including several exploratory analyses evaluating eight years of Prolia therapy from the open-label extension study of the pivotal Phase 3 fracture trial.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry

Wed Sep 10, 2014

Medical News Today

News from Annals of Internal Medicine, Sept. 9, 2014

For many younger adults, the penalty for not buying health insurance may be less than the price of the least expensive plan available under the Patient Protection and Affordable Care Act , according to a study being published in Annals of Internal Medicine . The ACA aims to expand health care coverage in part by providing subsidies to individuals with low annual incomes.

Comment?

Related Topix: Health Insurance, Health, Medicine

Thu Sep 04, 2014

Journal-Advocate

Community notices

One of the fastest-growing services at Branigan Library is e-books. The number of e-reader patrons at the library grows every day, but not everyone who wants to use them are comfortable the devices.

Comment?

Related Topix: Emerging Technology, Search Engines, Ipad, Science / Technology, Medicine, Health, Life, Food, Nutrition, Las Cruces, NM

Wed Sep 03, 2014

Medical News Today

Novel mode of action revealed for an osteoporosis drug

Raloxifene is a U.S. Food and Drug Administration -approved treatment for decreasing fracture risk in osteoporosis .

Comment?

Related Topix: Medicine, Evista, Raloxifene (generic), Health, Food and Drug Administration, Department of Energy, UC San Diego

Tue Sep 02, 2014

SFGate

Poor sleep linked to suicide

We have re-imagined our design in a bold new way. Before we roll it out for everyone, we are giving select readers an opportunity to try out the new design.

Comment?

Related Topix: Suicide, Depression, Health, Medicine, Nutrition, Breast Cancer, California

Mon Sep 01, 2014

World News Report

Naples Physical Therapy Facility Now Offering Kyphoplasty Procedures To Ease Pain Of Spinal Fracture

Jaffe Sports Medicine in Naples is offering Kyphoplasty as a pain management treatment for spinal fractures and compression caused by Osteoporosis.

Comment?

Related Topix: Physical Medicine & Rehabilitation, Medicine, Fracture, Naples, FL, Health

Sat Aug 30, 2014

Holtville Tribune

Osteoporosis medications can have negative effect on bone healing after tooth extraction

Removal of a tooth is usually a straightforward process that can be done by most general dentists.

Comment?

Related Topix: Medicine, Health, Dentistry, Surgery, Fosamax, Alendronate (generic)

Fri Aug 29, 2014

EurekAlert!

Revealing a novel mode of action for an osteoporosis drug

Raloxifene is a U.S. Food and Drug Administration -approved treatment for decreasing fracture risk in osteoporosis.

Comment?

Related Topix: Medicine, Evista, Raloxifene (generic), Health, Food and Drug Administration, Department of Energy, Purdue University, UC San Diego

•••
•••
•••
•••
•••
•••
•••
•••